AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.

The FDA granted priority review for Datroway based on results from the TROPION-Breast02 Phase III trial.

The stimulator of interferon genes (STING) pathway is a central mediator of innate immunity, sensing cytosolic DNA and triggering type I interferon ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

While its vehicle battery resurrection skills are uncertain at best, this device also offers other useful abilities.

ASCO is just around the corner, and as usual, there is a fertile crop of high-profile clinical trials to look out for among the late-breaker presentations. To follow – and in no particular order - are ...

AstraZeneca to showcase phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026: Cambridge, UK Monday, May 25, 2026, 12: ...

BioNTech sails into ASCO with two clinical readouts that underscore its pivot toward oncology beyond vaccines, even as the stock trades under mid-year pressure and investors weigh the pace of the ...